Skip to main content
OpenTrials
Completed

NCT Number: NCT02961985

Myocardial Infarction Register of the Saarland

The Myocardial Infarction Register Saarland (MIR-SL), is intended to collect data about the treatment of patients suffering from ST-elevation myocardial infarction (STEMI). It aims to provide current data on the implementation of guidelines for both, the interventional and adjuvant drug therapy of STEMI in daily clinical practice in the Saarland.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myocardial Infarction Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum Saarbruecken, Saarbrücken, Saarland, Germany

Loading trial locations.

About this study

The Myocardial Infarction Register Saarland (MIR-SL), is intended to collect data about the treatment of patients suffering from ST-elevation myocardial infarction (STEMI). It aims to provide current data on the implementation of guidelines for both, the interventional and adjuvant drug therapy of STEMI in daily clinical practice in the Saarland.

In order to obtain representative data for the Saarland, preferably all consecutive patients should be documented comprehensively in the University Hospital of the Saarland, the non-university hospitals with cardiac catheterization laboratory as well as in hospitals without cardiac catheterization laboratory .

MIR-SL is attended by all 22 hospitals in Saarland, that treat patients with acute STEMI. A follow-up will be carried out after three months, 12 months and five years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • signed informed consent

Exclusion criteria

  • age < 18 years
  • missing informed consent

Treatment and study plan

Primary outcomes

  1. Rate of reperfusion therapies

    Time frame: 24 hours

    Describe hospital daily routine in Germany

Secondary outcomes

  1. Time before reperfusion therapy

    Time frame: 24 hours

    pre-hospital time, intrahospital time, transfer time

  2. In-hospital mortality

    Time frame: 24 hours

    Describe mortality before discharge

Sponsors and collaborators

Lead sponsor

Stiftung Institut fuer Herzinfarktforschung

Other

Collaborators

  • Ministry of Social Affairs, Health, Women and Family of Saarland

Registry information

Official study title

Myokardinfarkt-Register Des Saarlandes (MIR-SL)

Acronym: MIR-SL

Important dates

Study start
2016
Primary completion
2018
Study completion
2023
First posted
Nov 11, 2016
Registry last updated
Apr 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.